Insights
MHRA and NICE collaboration: A new era for accelerating patient access to medicines
04 Nov 2025The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) have provided more details about a significant collaboration aimed at transforming the regulatory and health technology assessment processes in the UK. This MHRA and NICE partnership marks a pivotal step in expediting patient access to medicines while enhancing the UK’s position as a global leader in life sciences.
€160m fine warning of dangers of imposing resale prices on customers or interfering with discounts
04 Nov 2025Businesses might want to protect their downstream market, but this is riddled with dangers when they look to impose conditions on the minimum or actual prices or discount conditions on their customers. The €157m fines on Gucci, Chloé and Loewe provide a big warning sign to businesses of engaging with this.
Employment Rights Bill: Key implications for the Pharmaceuticals and Life Sciences Sector
04 Nov 2025The Employment Rights Bill will introduce significant changes impacting employers across all industries. For pharmaceuticals and life sciences organisations, these changes come as workforce expectations evolve and sustainability becomes a marker of good governance. Employers that align legal compliance with fair and transparent employment practices will be best placed to attract and retain skilled talent in a competitive market.
Is it safe for your business to embrace AI?
08 Oct 2025Legal considerations and practical tips for businesses in the pharmaceuticals and life sciences sector.
The MHRA launches the development of its new five-year strategy - can we predict their next steps?
08 Oct 2025The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that it is developing a new strategy to provide its direction, mission, values and focus through to 2030. What should we expect?
UK Life Sciences shows resilience and opportunity despite concerns over recent big pharma announcements
08 Oct 2025It's been a challenging few weeks for the UK life sciences sector. Following the breakdown of the talks with the Government to provide a more competitive reimbursement scheme for pharma, there have been a number of high-profile decisions that have created big concerns for the future of the sector. However, there have been some good news stories too, including a resilient message from MedCity - the life sciences arm of London and Partners, with whom VWV is a partner.
